Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 남은미 | * |
dc.contributor.author | 김규보 | * |
dc.date.accessioned | 2017-12-27T16:31:28Z | - |
dc.date.available | 2017-12-27T16:31:28Z | - |
dc.date.issued | 2017 | * |
dc.identifier.issn | 1341-9625 | * |
dc.identifier.other | OAK-20591 | * |
dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/239487 | - |
dc.description.abstract | Purpose: To investigate the significance of carbohydrate antigen 19-9 (CA19-9) levels for survival in locally advanced pancreatic cancer (LAPC) treated with concurrent chemoradiotherapy (CCRT). Methods/patients: We retrospectively reviewed data from 97 LAPC patients treated with CCRT between 2000 and 2013. CA19-9 levels (initial and post-CCRT) and their changes [{(post-CCRT CA19-9 level − initial CA19-9 level)/(initial CA19-9 level)} × 100] were analyzed for overall survival. A cut-off point of 37 U/mL was used to analyze initial and post-CCRT CA19-9 levels. In order to define an optimal cut-off point for change in CA19-9 level, the maxstat package of R was applied. Results: Median overall survival was 14.7 months (95% CI 13.4–16.0), and the 2-year survival rate was 16.5%. The estimated optimal cut-off point of CA19-9 level change was 94.4%. On univariate analyses, CA19-9 level change between initial and post-CCRT was significantly correlated with overall survival (median survival time 9.7 vs 16.3 months, p < 0.001). Multivariate analyses confirmed that CA19-9 level change from initial to post-CCRT was the only prognostic factor (p < 0.001). Conclusions: Change in CA19-9 level between initial and post-CCRT was a significant prognostic marker for overall survival in LAPC treated with CCRT. A CA19-9 level increase >94.4% might serve as a surrogate marker for poor survival in patients with LAPC undergoing CCRT, and the prognostic power surpassed other CA19-9 variables including initial and post-CCRT values. © 2017, Japan Society of Clinical Oncology. | * |
dc.language | English | * |
dc.publisher | Springer Tokyo | * |
dc.subject | CA19-9 | * |
dc.subject | Concurrent chemoradiotherapy | * |
dc.subject | Locally advanced pancreatic cancer | * |
dc.title | Change in carbohydrate antigen 19-9 level as a prognostic marker of overall survival in locally advanced pancreatic cancer treated with concurrent chemoradiotherapy | * |
dc.type | Article | * |
dc.relation.issue | 6 | * |
dc.relation.volume | 22 | * |
dc.relation.index | SCIE | * |
dc.relation.index | SCOPUS | * |
dc.relation.startpage | 1069 | * |
dc.relation.lastpage | 1075 | * |
dc.relation.journaltitle | International Journal of Clinical Oncology | * |
dc.identifier.doi | 10.1007/s10147-017-1129-7 | * |
dc.identifier.wosid | WOS:000414780900011 | * |
dc.identifier.scopusid | 2-s2.0-85018770563 | * |
dc.author.google | Kim Y.-J. | * |
dc.author.google | Koh H.K. | * |
dc.author.google | Chie E.K. | * |
dc.author.google | Oh D.-Y. | * |
dc.author.google | Bang Y.-J. | * |
dc.author.google | Nam E.M. | * |
dc.author.google | Kim K. | * |
dc.contributor.scopusid | 남은미(7005824288;57226666155) | * |
dc.contributor.scopusid | 김규보(8213302900) | * |
dc.date.modifydate | 20240301081003 | * |